Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | JUN | P05412 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | VCP | P55072 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898942 | 1.00 | CYP11B2 (0.59) | CYP11B2CYP11B1MAPTKMT2AMAPK1 | |
| SCHEMBL29691639 | 0.80 | CYP11B1 (0.86) | CYP11B2CYP11B1MAPTKMT2AMAPK1 | |
| SCHEMBL29691623 | 0.80 | CYP11B1 (0.86) | CYP11B2CYP11B1MAPTKMT2AMAPK1 | |
| SCHEMBL2327877 | 0.80 | CYP11B1 (0.59) | CYP11B2CYP11B1MAPTKMT2AMAPK1 | |
| SCHEMBL2327875 | 0.80 | CYP11B1 (0.59) | CYP11B2CYP11B1MAPTKMT2AMAPK1 | |
| SCHEMBL2384026 | 0.79 | — | — | |
| SCHEMBL29691532 | 0.78 | CYP11B1 (0.82) | CYP11B2CYP11B1MAPTKMT2AMAPK1 | |
| SCHEMBL29691548 | 0.78 | CYP11B1 (0.82) | CYP11B2CYP11B1MAPTKMT2AMAPK1 | |
| SCHEMBL29691514 | 0.78 | CYP11B1 (0.82) | CYP11B2CYP11B1MAPTKMT2AMAPK1 | |
| SCHEMBL29691464 | 0.78 | CYP11B1 (0.82) | CYP11B2CYP11B1MAPTKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080091014-A1 | Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates | ANHUI QUINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD. (CN) | 2008-04-17 | — | — | US | claimed |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | MEDCURIUS INC. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | MEDCURIUS INC. (CN) | 2023-09-14 | — | — | US | disclosed |
| WO-2021259143-A1 | PHARMACEUTICAL USE OF (E)-3-ARYLHETEROCYCLYL PROP-2-ENOIC ACID DERIVATIVES | 上海长车生物科技有限公司 | 2021-12-30 | — | — | WO | disclosed |
| CN-102481285-A | Use of derivatives of indole for the treatment of cancer | CENTRE NAT RECH SCIENT | 2012-05-30 | — | — | CN | disclosed |
| US-20080091014-A1 | Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates | ANHUI QUINGYUN PHARMACEUTICAL AND CHEMICAL CO., LTD. (CN) | 2008-04-17 | — | — | US | disclosed |
| US-7332622-B2 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGUKU KABUSHIKI KAISHA (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7332622-B2 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGUKU KABUSHIKI KAISHA (JP) | 2008-02-19 | — | — | US | disclosed |
| EP-1115697-B1 | UNSATURATED HYDROXIMIC ACID DERIVATIVES AS PARP INHIBITORS | GENE KUTATO KFT N (HU) | 2004-02-04 | — | — | EP | disclosed |
| US-6500823-B1 | ENERGY DEFICIENCY OF THE CELL CAUSED BY PARP INHIBITION, IN DIABETES COMPLICATIONS, IN OXYGEN DEFICIENT STATUS OF THE HEART AND BRAIN, IN NEURODEGENERATIVE DISEASES, IN THE TREATMENT OF AUTOIMMUNE AND/OR VIRAL DISEASES | N-GENE RESEARCH LABORATORIES, INC. | 2002-12-31 | — | — | US | disclosed |
| WO-2000014054-A1 | UNSATURATED HYDROXIMIC ACID DERIVATIVES AS PARP INHIBITORS | N-Gene Kutató Kft. (HU) | 2000-03-16 | — | — | WO | disclosed |
| EP-0500653-A4 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE | BIOCRYST INC (US) | 1995-08-23 | — | — | EP | disclosed |
| US-5286721-A | Antimicrobial agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-15 | — | — | US | disclosed |
| WO-1993023402-A1 | 3-AZETIDINYLTHIO-CARBAPENEME DERIVATIVES, THEIR PREPARATION AND USE AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-25 | — | — | WO | disclosed |
| EP-0506982-A1 | 1-AZABICYCLO 3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
| EP-0500653-A1 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE | BIOCRYST PHARMACEUTICALS INC. (US) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992006978-A1 | 1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-30 | — | — | WO | disclosed |
| WO-1991006548-A1 | INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE | BIOCRYST, INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| US-5008270-A | 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same | BIOCRYST, INC. (US) | 1991-04-16 | — | — | US | disclosed |
| US-4985433-A | 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same | BIOCRYST, INC. (US) | 1991-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | NFE2L2, NFE2, TXNRD2 | CYP11B2 366/4885CYP11B1 305/4885MAPT 3234/4885 |
| US-20080091014-A1 | Synthetic Method and Intermediates of Rosuvastatin Calcium and Preparation Methods of Intermediates | KCNN4, HCN4, CACNB4 | CYP11B2 674/4885CYP11B1 779/4885MAPT 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.